PortalPublikationenAnti-tumor activity of a B-cell receptor-targeted peptide in...

Anti-tumor activity of a B-cell receptor-targeted peptide in a novel disseminated lymphoma xenograft model.

Standard

Anti-tumor activity of a B-cell receptor-targeted peptide in a novel disseminated lymphoma xenograft model. / Wehr, Claudia; Müller, Fabian; Schüler, Julia; Tomann, Tina; Nitschke, Claudia; Seismann, Henning; Spillner, Edzard; Klingner, Kerstin; Schneider-Merck, Tanja; Binder, Mascha; Fiebig, Heinz-Herbert; Mertelsmann, Roland; Trepel, Martin.

in: INT J CANCER, Jahrgang 131, Nr. 2, 2, 2012, S. 10-20.

Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung

Harvard

Wehr, C, Müller, F, Schüler, J, Tomann, T, Nitschke, C, Seismann, H, Spillner, E, Klingner, K, Schneider-Merck, T, Binder, M, Fiebig, H-H, Mertelsmann, R & Trepel, M 2012, 'Anti-tumor activity of a B-cell receptor-targeted peptide in a novel disseminated lymphoma xenograft model.', INT J CANCER, Jg. 131, Nr. 2, 2, S. 10-20. <http://www.ncbi.nlm.nih.gov/pubmed/21953178?dopt=Citation>

APA

Wehr, C., Müller, F., Schüler, J., Tomann, T., Nitschke, C., Seismann, H., Spillner, E., Klingner, K., Schneider-Merck, T., Binder, M., Fiebig, H-H., Mertelsmann, R., & Trepel, M. (2012). Anti-tumor activity of a B-cell receptor-targeted peptide in a novel disseminated lymphoma xenograft model. INT J CANCER, 131(2), 10-20. [2]. http://www.ncbi.nlm.nih.gov/pubmed/21953178?dopt=Citation

Vancouver

Wehr C, Müller F, Schüler J, Tomann T, Nitschke C, Seismann H et al. Anti-tumor activity of a B-cell receptor-targeted peptide in a novel disseminated lymphoma xenograft model. INT J CANCER. 2012;131(2):10-20. 2.

Bibtex

@article{ca068d196ebe41c189b2d865822e15a8,
title = "Anti-tumor activity of a B-cell receptor-targeted peptide in a novel disseminated lymphoma xenograft model.",
abstract = "Receptor-targeted therapies have become standard in the treatment of various lymphomas. In view of its unparalleled specificity for the malignant B-cell clone, the B-cell receptor (BCR) on B cell lymphoma cells is a potential therapeutic target. We have used two BCR epitope mimicking peptides binding to the Burkitt's lymphoma cell lines CA46 and SUP-B8. We proved their functionality by demonstrating calcium flux and BCR-mediated endocytosis upon peptide receptor binding. Toxicity experiments in vitro via cross-linking of the BCR with tetramerized epitope mimics lead to apoptosis in both cell lines but was far more effective in SUP-B8 cells. We established a SUP-B8-based disseminated Burkitt's lymphoma model in NOD/SCID mice. Treatment of tumor-bearing mice with tetramerized epitope mimics had significant anti-tumor effects in vivo. We conclude that peptide-mediated, BCR-targeted therapy is a promising approach which may be explored and further developed for application in highly aggressive lymphoma.",
author = "Claudia Wehr and Fabian M{\"u}ller and Julia Sch{\"u}ler and Tina Tomann and Claudia Nitschke and Henning Seismann and Edzard Spillner and Kerstin Klingner and Tanja Schneider-Merck and Mascha Binder and Heinz-Herbert Fiebig and Roland Mertelsmann and Martin Trepel",
year = "2012",
language = "English",
volume = "131",
pages = "10--20",
journal = "INT J CANCER",
issn = "0020-7136",
publisher = "Wiley-Liss Inc.",
number = "2",

}

RIS

TY - JOUR

T1 - Anti-tumor activity of a B-cell receptor-targeted peptide in a novel disseminated lymphoma xenograft model.

AU - Wehr, Claudia

AU - Müller, Fabian

AU - Schüler, Julia

AU - Tomann, Tina

AU - Nitschke, Claudia

AU - Seismann, Henning

AU - Spillner, Edzard

AU - Klingner, Kerstin

AU - Schneider-Merck, Tanja

AU - Binder, Mascha

AU - Fiebig, Heinz-Herbert

AU - Mertelsmann, Roland

AU - Trepel, Martin

PY - 2012

Y1 - 2012

N2 - Receptor-targeted therapies have become standard in the treatment of various lymphomas. In view of its unparalleled specificity for the malignant B-cell clone, the B-cell receptor (BCR) on B cell lymphoma cells is a potential therapeutic target. We have used two BCR epitope mimicking peptides binding to the Burkitt's lymphoma cell lines CA46 and SUP-B8. We proved their functionality by demonstrating calcium flux and BCR-mediated endocytosis upon peptide receptor binding. Toxicity experiments in vitro via cross-linking of the BCR with tetramerized epitope mimics lead to apoptosis in both cell lines but was far more effective in SUP-B8 cells. We established a SUP-B8-based disseminated Burkitt's lymphoma model in NOD/SCID mice. Treatment of tumor-bearing mice with tetramerized epitope mimics had significant anti-tumor effects in vivo. We conclude that peptide-mediated, BCR-targeted therapy is a promising approach which may be explored and further developed for application in highly aggressive lymphoma.

AB - Receptor-targeted therapies have become standard in the treatment of various lymphomas. In view of its unparalleled specificity for the malignant B-cell clone, the B-cell receptor (BCR) on B cell lymphoma cells is a potential therapeutic target. We have used two BCR epitope mimicking peptides binding to the Burkitt's lymphoma cell lines CA46 and SUP-B8. We proved their functionality by demonstrating calcium flux and BCR-mediated endocytosis upon peptide receptor binding. Toxicity experiments in vitro via cross-linking of the BCR with tetramerized epitope mimics lead to apoptosis in both cell lines but was far more effective in SUP-B8 cells. We established a SUP-B8-based disseminated Burkitt's lymphoma model in NOD/SCID mice. Treatment of tumor-bearing mice with tetramerized epitope mimics had significant anti-tumor effects in vivo. We conclude that peptide-mediated, BCR-targeted therapy is a promising approach which may be explored and further developed for application in highly aggressive lymphoma.

M3 - SCORING: Journal article

VL - 131

SP - 10

EP - 20

JO - INT J CANCER

JF - INT J CANCER

SN - 0020-7136

IS - 2

M1 - 2

ER -